Personalised precision medicine has become a new paradigm in oncology treatment, offering hope for improved cancer treatments. Advances in multiplex genotyping and high-throughput genomic profiling by next-generation sequencing (NGS) allow clinicians and laboratory professionals to routinely gather therapy-relevant molecular information in a timely fashion, a condition that is required for true personalized medicine in the face of a growing list of molecularly targeted drugs*.
Thermo Fisher Scientific offers multiple solutions for solid tumor biomarker testing to aid in identifying those patients eligible for treatment, based on Ion Torrent and Oncomine NGS technology.
As IVD regulations and oncology drug and testing market needs are different in countries and regions around the world, we offer the following localized solutions:
The Oncomine Dx Target Test is an FDA-approved targeted NGS in vitro diagnostic test for non–small cell lung cancer (NSCLC) and cholangiocarcinoma (CC) that can simultaneously deliver multiple biomarker results for multiple targeted therapies from one sample within four days.
The Oncomine Dx Target Test is the first CE-IVD solid-tumor biomarker test based on targeted NGS that detects key biomarkers relevant to currently approved and investigative targeted therapies in solid tumors.
The Oncomine Solid Tumor DNA Kit and Oncomine Solid Tumor Fusion Transcript Kit are targeted NGS-based kits that enable the detection of multiple solid tumor DNA- and RNA-based biomarkers, including EGFR, BRAF, ALK, ROS1, KRAS, and NRAS. These kits can be used separately or together in a single workflow and offer a flexible solution for the preparation of targeted libraries for the detection of multiple actionable solid tumor biomarkers, particularly for NSCLC, colon cancer, and melanoma.
*Scientific Advances in Lung Cancer; 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.
For In Vitro Diagnostic Use.